These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 36698833)

  • 1. Rise of the planet of rare anemias: An update on emerging treatment strategies.
    Fattizzo B; Motta I
    Front Med (Lausanne); 2022; 9():1097426. PubMed ID: 36698833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular pharmacology in complement-mediated hemolytic disorders.
    Bortolotti M; Barcellini W; Fattizzo B
    Eur J Haematol; 2023 Sep; 111(3):326-336. PubMed ID: 37308291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Novel anti-complement therapeutics for hemolytic anemia].
    Nishimura JI
    Rinsho Ketsueki; 2023; 64(6):466-473. PubMed ID: 37407469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel insights into the treatment of complement-mediated hemolytic anemias.
    Berentsen S; Hill A; Hill QA; Tvedt THA; Michel M
    Ther Adv Hematol; 2019; 10():2040620719873321. PubMed ID: 31523413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New Therapies for the Treatment of Warm Autoimmune Hemolytic Anemia.
    Fattizzo B; Barcellini W
    Transfus Med Rev; 2022 Oct; 36(4):175-180. PubMed ID: 36182620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Novel therapeutic agents for hemolytic anemia].
    Nishimura JI
    Rinsho Ketsueki; 2023; 64(9):884-891. PubMed ID: 37793862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploring treatment strategies for paroxysmal nocturnal hemoglobinuria: an overview of registered clinical trials.
    Peixoto VP; Prudêncio C; Vieira M
    Curr Med Res Opin; 2024 May; ():1-11. PubMed ID: 38727420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Case report: Transfusion independence and abolition of extravascular hemolysis in a PNH patient treated with pegcetacoplan.
    Fattizzo B; Versino F; Zaninoni A; Marcello APML; Vercellati C; Artuso S; Barcellini W
    Front Immunol; 2022; 13():1060923. PubMed ID: 36532073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mitapivat for sickle cell disease and thalassemia.
    Pilo F; Angelucci E
    Drugs Today (Barc); 2023 Mar; 59(3):125-134. PubMed ID: 36847623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovering C3 targeting therapies for paroxysmal nocturnal hemoglobinuria: Achievements and pitfalls.
    Risitano AM; Peffault de Latour R; Marano L; Frieri C
    Semin Immunol; 2022 Jan; 59():101618. PubMed ID: 35764467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of complement activation in thrombosis and hemolytic anemias.
    Chapin J; Terry HS; Kleinert D; Laurence J
    Transfus Apher Sci; 2016 Apr; 54(2):191-8. PubMed ID: 27156108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advancing therapeutic complement inhibition in hematologic diseases: PNH and beyond.
    Gavriilaki E; de Latour RP; Risitano AM
    Blood; 2022 Jun; 139(25):3571-3582. PubMed ID: 34482398
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic complement inhibition in complement-mediated hemolytic anemias: Past, present and future.
    Risitano AM; Marotta S
    Semin Immunol; 2016 Jun; 28(3):223-40. PubMed ID: 27346521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody based therapeutics for autoimmune hemolytic anemia.
    Cavallaro F; Barcellini W; Fattizzo B
    Expert Opin Biol Ther; 2023; 23(12):1227-1237. PubMed ID: 37874225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative effectiveness of pegcetacoplan versus ravulizumab in patients with paroxysmal nocturnal hemoglobinuria previously treated with eculizumab: a matching-adjusted indirect comparison.
    Bhak RH; Mody-Patel N; Baver SB; Kunzweiler C; Yee CW; Sundaresan S; Swartz N; Duh MS; Krishnan S; Sarda SP
    Curr Med Res Opin; 2021 Nov; 37(11):1913-1923. PubMed ID: 34445916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New Insights in Autoimmune Hemolytic Anemia: From Pathogenesis to Therapy Stage 1.
    Barcellini W; Zaninoni A; Giannotta JA; Fattizzo B
    J Clin Med; 2020 Nov; 9(12):. PubMed ID: 33261023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel Monoclonal Antibody Therapy in a Patient With Treatment-Refractory Warm Autoimmune Hemolytic Anemia.
    Tahhan F; Huynh B; Xu P
    Cureus; 2022 Jun; 14(6):e26051. PubMed ID: 35747120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging drugs for the treatment of paroxysmal nocturnal hemoglobinuria.
    Frieri C; Peffault de Latour R; Sicre De Fontbrune F
    Expert Opin Emerg Drugs; 2022 Mar; 27(1):33-43. PubMed ID: 35078384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paroxysmal nocturnal hemoglobinuria and the complement system: recent insights and novel anticomplement strategies.
    Risitano AM
    Adv Exp Med Biol; 2013; 735():155-72. PubMed ID: 23402025
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of C3 with pegcetacoplan results in normalization of hemolysis markers in paroxysmal nocturnal hemoglobinuria.
    Wong RSM; Pullon HWH; Amine I; Bogdanovic A; Deschatelets P; Francois CG; Ignatova K; Issaragrisil S; Niparuck P; Numbenjapon T; Roman E; Sathar J; Xu R; Al-Adhami M; Tan L; Tse E; Grossi FV
    Ann Hematol; 2022 Sep; 101(9):1971-1986. PubMed ID: 35869170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.